195 related articles for article (PubMed ID: 36996780)
1. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
5. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
7. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
8. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
11. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
13. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
14. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
[TBL] [Abstract][Full Text] [Related]
15. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
Larenas-Linnemann D
Curr Allergy Asthma Rep; 2023 Dec; 23(12):655-664. PubMed ID: 38064133
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
Kocatürk E; Başkan EB; Küçük ÖS; Özdemir M; Örnek S; Can PK; Haşal E; Engin B; Atakan N; Alpsoy E
An Bras Dermatol; 2022; 97(5):592-600. PubMed ID: 35853771
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
